THE PROGNOSTIC MARKERS, CURRENT TREATMENT STRATEGIES AND THE LONG TERM PROGNOSIS FOR PROLIFERATIVE FORMS OF LUPUS NEPHRITIS

Year 2003, Volume: 16 Issue: 4, 287 - 291, 03.12.2016

Serhan Tuğlular , Şule Yavuz

Abstract

Renal manifestations of systemic lupus erytematosus (SLE) are highly variable in clinical presentation, ranging from mild asymptomatic proteinuria to rapidly progressive glomerulonephritis leading to end stage renal disease.
Renal biopsy evaluated by light microscopy, immunofluorescence and electron microscopy where possible, provides invaluable information for the proper histopathological classification and for assessing the disease activity and chronicity. The World Health Organization (WHO) classification of lupus nephritis is a practical and widely accepted system for categorizing the main renal lesions observed on biopsies of patients with lupus nephritis(Table I) (1). The focal and diffuse proliferative forms of lupus nephritis corresponding to WHO class III and IV have the worst prognosis, leading to ESRD in 20-30% of the cases (2). A substantial proportion of patients with class III nephritis progress to class IV disease and it has been suggested that these two classes are qualitatively similar and simply reflect milder or more severe stages respectively (3).
The aim of this article is to overview the prognostic markers, the current treatment strategies and the long term prognosis for the latter forms of lupus nephritis.

References

• Gladman DD, Urowitz Mil, Cole E, Ritchie S, Chang CM, Churg J. Kidney biopsy in SLE. I. A clinical-morphologic evaluation. Q J Med 1989; 73:1 125-1 133.
• Schwartz MM. Lupus nephritis. Curr Opin Mephrol My pert 1995; 4: 162-168.
• Grande JF, Baiow JE. Renal biopsy in lupus nephritis.Lupus I998;7:61 1-617.
• Austin IIA 3rd, Rlippel JH, Baiow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. M Engl J Med 1986;314:614-619.
• McLaughlin JR, Bombardier C, Farewell VT, Gladman DD, Urowitz MB. Ridney biopsy in systemic lupus erythematosus. III. Survival analysis controlling for clinical and laboratory variables. Arthritis Rheum 1994:37:559-567.
• Con Ion PJ, Fischer CA, Levesque MC, et al. Clinical, biochemical and pathological predictors of poor response to intravenous cyclophosphamide in patients with proliferative lupus nephritis. Clin Mephrol 1996;46:170-175.
• Moroni G, Quaglini S, Maccario M, Banfi G, Ponticelli C.Mephritic flares" are predictors of bad long-term renal outcome in lupus nephritis. Ridney Int 1996;50:2047-2053.
• Leaker B, Fairley RF, Dowling J, et al. Lupus
• Mephritis: clinical and pathological
• correlation. Q J Med 1987; 62: 163-179
• Donadio J V, flolley RE, Ferguson RM, et al. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. M Eng J Med 1978; 299; 1151-1155
• Ciruelo E, De la Cruz J, Lopez I, et al. Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide. Arthritis Rheum 1996; 39:2028-2034
• I I. Boumpas DT, Austin MA 3rd, Vaughn EM, et at. Controlled trial of pulse méthylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340:74 I-745
• Ponticelli C, Moroni G. Flares in lupus nephritis: Incidence, impact on renal survival and management. Lupus 1998; 7: 635-638
• Fremeaux-Bacchl V, Moel LM, Schifferli JA. Mo lupus nephritis in the absence of antiC I q autoantibodies? Mephrol Dial Transplant 2002;17:2041-2043.
• Gladman DD, Urowitz MB, Esdaile JM, et al.Guidelines for referral and management of systemic lupus erythematosus in adults. Arthritis Rheum 1999;42:1 785-96
• Baiow JE, Boumpas DT, Fessier BJ, et al. Management of lupus nephritis. Ridney int 1996;49 Supp53:S88-92
• Bansal VR, Beto JA. Treatment of lupus nephritis: a meta-analysis of clinical trials. Am J Ridney Dis 199 7;29:193-199.
• Felson DT, Anderson J. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone In lupus nephritis. Results of a pooled analysis. M Engl J Med 1984:311:1528-1533.
• Baiow JE, Austin MA 3rd, Muenz LR, et al. Effect of treatment on the evolution of renal abnormalities in lupus nephritis. M Engl J Med 1984;31 1:491-495.
• Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 1991;34:945-950.
• Cameron JS. Lupus and lupus nephritis in children. Ad v Mephrol Meeker Mosp 1993;22:59-1 19
• Moussiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis. Arthritis Rheum 2002;46:2121 - 2131
• Van Brüggen MC, Walgreen B, Rijke TP, Berden JM. Attenuation of murine lupus nephritis by mycophenolate mofetil: J Am Soc Mephrol 1998;9:1407-1415.
• Chan TM, Li FR, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Mong Rong-Guangzhou Mephrology Study Group. M Engl J Med 2000:343:1 156-1 162.
• Silverman GJ, Weisman S. Rltuximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 2003;48:1484-1492.